On July 1, 2022 4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drugs derived from the microbiome, reported that following the appointment of administrators on 24 June 2022, recruitment of new patients into ongoing clinical studies will be temporarily paused (Press release, 4d Pharma, JUL 1, 2022, View Source [SID1234616465]). The studies impacted are:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

1)the Phase I/II study of MRx0518, in combination with KEYTRUDA (pembrolizumab), in patients with solid tumors. This study is currently in Part B and has met its primary efficacy endpoint early in the renal cell carcinoma group, as announced on 23 March 2022, having previously successfully completed Part A as announced on 11 May 2020;
2)the Phase II clinical trial of MRx0518, in combination with BAVENCIO (avelumab), in patients with urothelial carcinoma;
3)the Phase I study of MRx0518 in patients with pancreatic cancer;
4)the Phase I/II study of MRx-4DP0004 in patients with asthma. Part A of this study was successfully completed as announced on 13 December 2021 ; and
5)the Phase I study of MRx0005 or MRx0029 in patients with Parkinson’s disease.

4D pharma is working with the administrators to enable an exit from administration as soon as possible and, in the event that the company does exit administration, currently plans to recommence recruitment so long as additional capital funding is secured. Further announcements will be made in due course.